| Literature DB >> 35330445 |
Yu-Chen Chen1,2, Hao-Wei Chen1,2,3, Shu-Pin Huang1,2, Szu-Huai Lin4, Ting-Yin Chu5, Ching-Chia Li1,2, Yung-Shun Juan1,2, Wen-Jeng Wu1,2.
Abstract
The seasonal and meteorological factors in predicting infections after urological interventions have not been systematically evaluated. This study aimed to determine the seasonality and the effects of the weather on the risk and severity of infectious complications (IC) after a transrectal ultrasound-guided prostate biopsy (TRUS-Bx). Using retrospectively collected data at the tertiary care hospital in Taiwan, we investigated the seasonal and meteorological differences in IC after TRUS-Bx. The IC included urinary tract infection (UTI), sepsis, and a positive culture finding (PCF). The severity was assessed on the basis of the Common Terminology Criteria for Adverse Events grading system. The prevalences of the infectious complications (UTI, sepsis, PCF and grade ≥ 3 IC) were significantly higher in the summer than in the winter. Monthly temperature and average humidity were significant factors for IC. After adjusting the demographic factors, multivariate regression revealed that UTI, sepsis, PCF, and grade ≥ 3 IC increased by 12.1%, 16.2%, 21.3%, and 18.6% for every 1 °C increase in the monthly average temperature, respectively (UTI: p = 0.010; sepsis: p = 0.046; PCF: p = 0.037; grade ≥ 3 IC: p = 0.021). In conclusion, the development and severity of IC after TRUS-Bx had significant seasonality. These were dose-dependently associated with warmer weather. Infectious signs after TRUS-Bx should be monitored more closely and actively during warm weather.Entities:
Keywords: infection; prostate; seasonality; sepsis; temperature; transrectal; weather
Year: 2022 PMID: 35330445 PMCID: PMC8954785 DOI: 10.3390/jpm12030446
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Patients’ baseline characteristic over transrectal ultrasound-guided prostate biopsy.
| Characteristics | All Patients |
|---|---|
| Patients, | 851 |
| Age, years, median (range) | 67 (33–92) |
| BMI, kg/m2, median (range) | 24.7 (15.1–40.2) |
| PSA level, ng/dL, median (range) | 10.9 (0.7–5342) |
| Prostate volume, mL, median (range) | 44.9 (10.6–182.3) |
| PSA density, ng/mL2, median (range) a | 0.27 (0.02–90.3) |
| Biopsy pathological result, | |
| No malignancy | 593 (69.7%) |
| ISUP grade 1 | 69 (8.1%) |
| ISUP grade 2 | 22 (2.6%) |
| ISUP grade 3 | 25 (2.9%) |
| ISUP grade 4 | 66 (7.8%) |
| ISUP grade 5 | 76 (8.9%) |
| Diabetes, | 181 (21.3%) |
| Hypertension, | 405 (47.6%) |
a PSA density was calculated as total PSA (ng/mL) divided by prostate volume (mL). Abbreviations: BMI = body mass index; PSA = prostate-specific antigen; ISUP = International Society of Urological Pathology.
Baseline characteristics and incidence of infectious complication after TRUS-Bx per season and comparisons among different seasons.
| Subgroup | |||||
|---|---|---|---|---|---|
| Spring | Summer | Fall | Winter | ||
|
| |||||
| Age, years, median | 67 | 66 | 69 | 68 | 0.675 |
| BMI, kg/m2, median | 24.8 | 24.7 | 24.4 | 24.7 | 0.209 |
| PSA level, ng/dL, median | 10.9 | 11.0 | 11.0 | 10.2 | 0.852 |
| Prostate volume, mL, median | 46.4 | 47.0 | 42.0 | 42.8 | 0.537 |
| PSA density, ng/mL2, median b | 0.26 | 0.27 | 0.27 | 0.26 | 0.744 |
| Positive biopsy result, | 55 (26.2%) | 63 (31.5%) | 84 (34.4%) | 56 (28.4%) | 0.275 |
| Diabetes, | 44 (21.0%) | 42 (21.0%) | 59 (24.2%) | 36 (18.3%) | 0.527 |
| Hypertension, | 93 (44.3%) | 99 (49.5%) | 116 (47.5%) | 97 (49.2%) | 0.726 |
|
| |||||
| Urinary tract infection, | 13 (6.1%) | 26 (13%) a | 11 (4.5%) | 7 (3.6%) | <0.001 |
| Sepsis, | 6 (2.9%) | 11 (5.5%) a | 4 (1.6%) | 1 (0.6%) | 0.011 |
| Positive culture findings, | 3 (1.4%) | 9 (4.5%) a | 4 (1.6%) | 1(0.6%) | 0.028 |
|
| 0.002 | ||||
| Grade 2, | 7 (3.3%) | 14 (7.0%) | 6 (2.5%) | 6 (3.0%) | |
| 6 (2.9%) | 13 (6.6%) a | 4 (1.6%) | 2 (1.0%) | ||
a Versus winter (p < 0.05). b PSA density was calculated as total PSA (ng/mL) divided by prostate volume (mL). Abbreviations: TRUS-Bx = transrectal ultrasound-guided prostate biopsy; CTCAE = Common Terminology Criteria for Adverse Events, version 5.
Figure 1The distribution of seasonal infectious complications rates and temperatures in the continuous 5 year time period in Kaohsiung, Taiwan. The column represents the seasonal rate of infectious complications after a transrectal ultrasound-guided prostate biopsy (black column: urinary tract infection; gray column: sepsis; white column: positive culture finding). The line represents the average monthly temperature during the season (black solid line: average temperature; dense dotted line: lowest temperature; loose dotted line: highest temperature).
Univariable analysis of monthly meteorological parameters for infectious complications.
| Variables | UTI | Sepsis | PCF | CTCAE Grade ≥ 3 | ||||
|---|---|---|---|---|---|---|---|---|
| OR | OR | OR | OR | |||||
| Average temperature | 1.117 | 0.012 a | 1.156 | 0.052 | 1.194 | 0.051 | 1.180 | 0.024 a |
| Highest temperature | 1.180 | 0.007 a | 1.224 | 0.041 a | 1.266 | 0.039 a | 1.243 | 0.021 a |
| Lowest temperature | 1.074 | 0.019 a | 1.082 | 0.110 | 1.099 | 0.106 | 1.101 | 0.047 a |
| Average humidity | 1.100 | 0.007 a | 1.076 | 0.176 | 1.136 | 0.052 | 1.097 | 0.074 |
| Precipitation | 1.001 | 0.111 | 1.001 | 0.406 | 1.001 | 0.211 | 1.001 | 0.245 |
| Sun hours | 1.005 | 0.171 | 1.002 | 0.685 | 0.996 | 0.552 | 1.001 | 0.785 |
| 10 min wind speed | 1.061 | 0.144 | 1.038 | 0.578 | 1.091 | 0.201 | 1.054 | 0.389 |
ap < 0.05. Abbreviations: UTI = urinary tract infection; PCF = positive culture finding; CTCAE = Common Terminology Criteria for Adverse Events, version 5; OR = odds ratio; CI = confidence interval.
Multiple logistic regression of potential factors on the infectious complications after TRUS-Bx.
| Variables | UTI | Sepsis | PCF | CTCAE Grade ≥ 3 | ||||
|---|---|---|---|---|---|---|---|---|
| Adjusted OR (95% CI) | Adjusted OR | Adjusted OR (95% CI) | Adjusted OR (95% CI) | |||||
| Age | 1.000 | 0.987 | 0.996 | 0.867 | 1.012 | 0.691 | 1.008 | 0.740 |
| BMI | 1.010 | 0.827 | 0.916 | 0.243 | 0.918 | 0.309 | 0.922 | 0.245 |
| PSA level | 1.000 | 0.242 | 1.001 | 0.140 | 1.000 | 0.939 | 1.000 | 0.172 |
| Prostate volume | 1.008 | 1.154 | 1.010 | 0.247 | 1.019 | 0.037 a | 1.009 | 0.288 |
| Biopsy pathological result | ||||||||
| No malignancy | Ref. | Ref. | Ref. | Ref. | ||||
| Malignancy | 0.819 | 0.550 | 1.212 | 0.704 | 1.359 | 0.588 | 0.881 | 0.789 |
| Diabetes | 0.910 | 0.789 | 0.543 | 0.360 | 0.830 | 0.780 | 1.555 | 0.450 |
| Hypertension | 1.248 | 0.449 | 0.923 | 0.864 | 0.766 | 0.617 | 1.025 | 0.955 |
| The involvement of | 0.864 | 0.601 | 1.100 | 0.833 | 0.803 | 0.661 | 0.893 | 0.790 |
| Monthly average temperature | 1.121 | 0.010 a | 1.162 | 0.046 a | 1.213 | 0.037 a | 1.186 | 0.021 a |
ap < 0.05. Abbreviations: TRUS-Bx = transrectal ultrasound-guided prostate biopsy; UTI = urinary tract infection; PCF = positive culture finding; CTCAE = Common Terminology Criteria for Adverse Events, version 5, OR = odds ratio, CI = confidence interval, BMI = body mass index, PSA = prostate-specific antigen.